Opko Health, Inc.
4400 Biscayne Boulevard
Miami
Florida
33137
United States
Tel: 305-575-4100
Website: http://www.opko.com/
Email: contact@opko.com
278 articles with Opko Health, Inc.
-
OPKO Health Reports 2021 Second Quarter Business Highlights and Financial Results
7/29/2021
OPKO Health, Inc. reports business highlights and financial results for the three months ended June 30, 2021.
-
OPKO Health to Report Second Quarter 2021 Financial Results on July 29, 2021
7/20/2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended June 30, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, July 29, 2021.
-
OPKO Health to Present at the Ladenburg Thalmann Healthcare Conference
7/8/2021
OPKO Health, Inc. announced that management will be participating in the Ladenburg Thalmann Healthcare Conference being held virtually July 13-14, 2021.
-
OPKO Health Appoints Katherine Stueland as President and CEO of GeneDx
6/22/2021
OPKO Health, Inc. announced the appointment of Katherine Stueland as President and Chief Executive Officer of GeneDx, Inc., the global genomics subsidiary of OPKO’s BioReference Laboratories.
-
OPKO Health to Develop and Commercialize RAYALDEE® in Greater China with Nicoya Therapeutics
6/21/2021
OPKO Health, Inc. (NASDAQ: OPK) today announced that its subsidiary EirGen Pharma has entered into an agreement with Nicoya Macau Limited, an affiliate of Nicoya Therapeutics (Nicoya), for the development and commercialization in Greater China (mainland China, Hong Kong, Macau and Taiwan) of RAYALDEE ® for the treatment of secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD).
-
OPKO Health Announces Sale of its Sterile Fill and Finish Manufacturing Facility in Ireland
6/17/2021
OPKO Health, Inc. announces that its subsidiary, EirGen Pharma, Ltd., has entered into a definitive agreement to sell one of its facilities in Waterford, Ireland to Horizon Therapeutics plc for $65 million in cash less certain assumed and accrued liabilities relating to transferred employees.
-
OPKO Health to Participate in the Jefferies Virtual Healthcare Conference - May 27, 2021
5/27/2021
OPKO Health, Inc. announced that management will be participating in the Jefferies Virtual Healthcare Conference being held June 1-4, 2021.
-
OPKO Health Reports Transfer of Licensed Rights to RAYALDEE® in Japan to Vifor
5/24/2021
OPKO Health, Inc. (NASDAQ: OPK) today announced a transfer of the licensed rights to RAYALDEE ® in Japan from Japan Tobacco Inc. (JT) to Vifor Fresenius Medical Care Renal Pharma (VFMCRP). On May 17, 2021, JT notified OPKO of its decision to terminate the exclusive agreement with OPKO’s subsidiary, EirGen Pharma, Ltd., for the development and commercialization of RAYALDEE ® in Japan based on a comprehensive review of its development pipeline.
-
OPKO Health Reports 2021 First Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today
4/28/2021
OPKO Health, Inc. reports business highlights and financial results for the three months ended March 31, 2021.
-
OPKO Health to Report First Quarter 2021 Financial Results on April 28, 2021
4/22/2021
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended March 31, 2021, as well as discuss financial guidance, after the close of the U.S. financial markets on Wednesday, April 28, 2021.
-
OPKO Health Reports 2020 Fourth Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today
2/18/2021
OPKO Health, Inc. reports business highlights and financial results for the three months ended December 31, 2020.
-
OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021
2/3/2021
OPKO Health, Inc. plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, February 18, 2021.
-
OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference
1/5/2021
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39 th Annual J.P. Morgan Healthcare Conference being held virtually on January 11-14, 2021. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 13 th at 3:40 p.m. Eastern time. The presentation will be webcast live and available for replay in the Investors section of OPKO Health’s website and accessibl
-
Pfizer and OPKO Health are one step closer to receiving approval for their jointly developed pediatric growth hormone deficiency drug, somatrogon, after the U.S. FDA recently accepted the companies’ regulatory submission for the therapy.
-
OPKO Health to Participate in Three Upcoming Investment Conferences
11/11/2020
OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.
-
OPKO Health Reports 2020 Third Quarter Business Highlights and Financial ResultsConference call begins at 4:30 p.m. Eastern time today
10/29/2020
OPKO Health, Inc. reports business highlights and financial results for the three months ended September 30, 2020.
-
OPKO Health to Report Third Quarter 2020 Financial Results on October 29, 2020
10/13/2020
OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended September 30, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, October 29, 2020. OPKO’s senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on October 29 th beginning at 4:30 p.m. Eastern time. CONFERENCE
-
Clinical Catch-Up: October 5-9
10/12/2020
It was a moderately busy week for clinical trial news. Here’s a look. -
Pfizer Announces Positive Phase 3 Top-line Results for Once-Weekly Investigational Long-Acting Human Growth Hormone to Treat Children with Growth Hormone Deficiency
10/8/2020
Pfizer Inc. and OPKO Health Inc. announced that C0311002, a Phase 3, randomized, multicenter, open-label, crossover study evaluating somatrogon dosed once-weekly in children 3 to <18 years of age with growth hormone deficiency, met its primary endpoint of improved treatment burden compared to GENOTROPIN® for injection administered once-daily.
-
Pfizer and Opko Health reported their Phase III clinical trial of somatrogan met the primary endpoint compared to Genotropin (somatropin) for treating children 3 to 18 years of age with growth hormone deficiency.